Meningioma Pipeline guide defines meningioma as a diverse set of tumors arising from the meninges, the membranous layers surrounding the central nervous system. Many meningioma’s produce no symptoms throughout a person's life, and if discovered, require no treatment other than periodic observation. Meningioma Pipeline Market Research Report provides the latest projects and drug profiles with key companies.
Introduction:
A meningioma is a type of tumor that develops from the meninges, the membrane that surrounds the brain and spinal cord. There are three layers of meninges, called the dura mater, arachnoid and pia mater. Most meningioma’s (90%) are categorized as benign tumors, with the remaining 10% being atypical or malignant. There is no obvious cause of a meningioma. However, this type of brain tumor is about three times more common in women than in men. A meningioma can cause symptoms by pressing on the brain or spinal cord.
Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1057906 .
The Pharmaceutical and Healthcare latest pipeline guide Meningioma Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Key Company Profiles:
Arno Therapeutics Inc
AstraZeneca Plc
Boehringer Ingelheim GmbH
GlaxoSmithKline Plc
Novartis AG
Pharma Mar SA
Progenics Pharmaceuticals Inc
Meningioma Drug Profiles
afatinib dimaleate Drug Profile, AR-42 Drug Profile, Edotreotide Labeled Yttrium 90 Drug Profile, GSK-2256098 Drug Profile, HXR-9 Drug Profile, pasireotide ER Drug Profile, selumetinib sulfate Drug Profile, trabectedin Drug Profile, vistusertib Drug Profile.

Inquire more on this Research Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1057906
Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
The pipeline guide provides a snapshot of the global therapeutic landscape of Meningioma (Oncology).
The pipeline guide reviews pipeline therapeutics for Meningioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
The pipeline guide reviews key companies involved in Meningioma (Oncology) therapeutics and enlists all their major and minor projects.
The pipeline guide evaluates Meningioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
The pipeline guide reviews latest news related to pipeline therapeutics for Meningioma (Oncology).
Purchase this research report Direct from http://www.reportsnreports.com/purchase.aspx?name=1057906 .
Table of Contents:
Meningioma Overview
Meningioma Therapeutics Development
Meningioma Pipeline Overview
Meningioma Pipeline by Companies
Meningioma Therapeutics Assessment
Meningioma Companies Involved in Therapeutics Development
Meningioma Drug Profiles
Meningioma Dormant Projects
Meningioma Product Development Milestones and more…

List of Tables.
Number of Products under Development for Meningioma, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Meningioma Pipeline by Arno Therapeutics Inc, H1 2017
Meningioma Pipeline by AstraZeneca Plc, H1 2017
Meningioma Pipeline by Boehringer Ingelheim GmbH, H1 2017
Meningioma Pipeline by GlaxoSmithKline Plc, H1 2017
Meningioma Pipeline by Novartis AG, H1 2017
Meningioma Pipeline by Pharma Mar SA, H1 2017
Meningioma Pipeline by Progenics Pharmaceuticals Inc, H1 2017
Meningioma Dormant Projects, H1 2017
Meningioma Discontinued Products, H1 2017

About Us:
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on [email protected] with your contact details.